CE

Sigma-Aldrich's Buyout by Merck KGaA Cleared in Brazil

A generic image of stock metrics Credit: Shutterstock photo

Lab chemical and life sciences company Sigma-Aldrich 's SIAL proposed acquisition by Germany's Merck KGaA has secured antitrust clearance in Brazil. Sigma-Aldrich has obtained an unconditional approval from Brazil's Council for Economic Defense ("CADE"), the final outstanding approval needed for the transaction.

The approval follows the recently received antitrust clearances from the competition authorities of Israel and South Korea. The clearance by CADE will be effective after a waiting period of 15 days. The deal was also cleared by the European Commission ("EC") and Chinese Ministry of Commerce in Jun 2015.

The transaction is still subject to Sigma-Aldrich's fulfillment of the commitments made to the EC following the latter's conditional approval. Sigma-Aldrich and Merck KGaA have agreed to dispose parts of Sigma-Aldrich's solvents and inorganics business in Europe to fulfill those commitments. Both companies are looking to close the deal in third-quarter 2015.

Sigma-Aldrich, on Sep 22, 2014, announced that Merck KGaA has agreed to buy it for $17 billion. Under the deal terms, Merck KGaA will buy all of the outstanding shares of Sigma-Aldrich for $140 per share in cash.

The deal is expected to be accretive to Merck KGaA's earnings per share and also offer annual synergies of roughly $340 million, expected to be fully realized within three years after transaction closure.

The merger will create a big player in the $130 billion global life sciences industry. The integrated company will be able to cater life science customers globally with a highly attractive set of established brands and an efficient supply chain that can facilitate the delivery of over 300,000 products. The customers will benefit from the offering of a vast array of complementary products and capabilities.

Sigma-Aldrich is a Zacks Rank #3 (Hold).

Better-ranked stocks in the chemicals space include Innospec Inc. IOSP , Celanese Corporation CE and The Dow Chemical Company DOW . While Innospec sports a Zacks Rank #1 (Strong Buy), Celanese and Dow hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SIGMA ALDRICH (SIAL): Free Stock Analysis Report

DOW CHEMICAL (DOW): Free Stock Analysis Report

CELANESE CP-A (CE): Free Stock Analysis Report

INNOSPEC INC (IOSP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.